ReCode Therapeutics is a private company founded in 2015 in the USA. The company develops precision genetic medicines using a proprietary delivery platform for the treatment of various genetic diseases, including cystic fibrosis and primary ciliary dyskinesia. ReCode Therapeutics is a multi-platform company developing non-viral nanoparticles for the delivery of diverse RNA- and protein-based therapeutics to targeted tissues and first-in-class tRNA NanoCorrectors for the correction of nonsense mutations causing cystic fibrosis and other diseases.

ReCode Therapeutics

MOMA Therapeutics focuses on discovering the next generation of precision medicines by targeting the molecular machines underlying human disease.

MOMA Therapeutics

Prenosis develops precision medicine tools and implements them in real time for acute care settings, focusing on personalizing healthcare based on individual biology. They leverage their Immunix precision medicine platform and have created the FDA authorized Sepsis ImmunoScore.

Prenosis

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

MPM Capital

Hunt Technology Ventures

Vida Ventures

Colt Ventures

OrbiMed

OUP (Osage University Partners)

Leaps by Bayer

Solasta Ventures

Bioluminescence Ventures

EcoR1 Capital

Pfizer Venture Investments

Sanofi Ventures

Amgen Ventures

Tekla Capital Management

NS Investment

Matrix Capital Management

Cystic Fibrosis Foundation

We're thrilled to announce that the first patient has been dosed in our Phase 1 clinical trial of RCT1100, a novel mRNA-based medicine for patients with primary ciliary dyskinesia (PCD) caused by DNAI1 gene mutations.

This marks a significant step in our efforts to bring innovative therapies to PCD patients who currently have no approved treatment options. RCT1100, developed using our proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform, is designed to restore ciliary function by targeting the disease's root cause.

As we advance this trial, we extend our heartfelt thanks to the PCD community for their ongoing support. Stay tuned for more updates on this groundbreaking journey!

Learn more at https://ThinkPCD.com, and read the full press release here:
https://lnkd.in/guA6BSGR

#pcd #geneticmedicines #patientsfirst #PCDfoundation

As we welcome the New Year, all of us at ReCode Therapeutics are filled with excitement and optimism. 2024 marks not just a change in the calendar but a renewed opportunity for discovery and innovation in our quest to transform the lives of those living with genetic diseases.

We send our well wishes for a year filled with health, happiness, and achievement. To a joyous and prosperous New Year!

As the holiday season unfolds, ReCode Therapeutics extends our warmest wishes to our community, partners, and the families we serve. This time of year reminds us of the importance of connection and compassion.

May this season bring joy, peace, and rejuvenation to you and your loved ones. 

Happy Holidays to all!

#HappyHolidays #TeamReCode

Join the ReCode Therapeutics team, where your passions and drive find a welcoming home. Here, our mantra is clear: "Patients first, always." 

But we're about more than just our platforms. At ReCode, we cultivate an environment where imagination flourishes, passions are fueled, and every voice is heard and valued. Our dedication to diversity and inclusivity has proudly earned us Best Place to Work recognition by the San Francisco Business Times and Silicon Valley Business Journal.

Whether you're a seasoned scientist or a nascent graduate, we have an array of opportunities across various disciplines.

ReCode Your Future:
https://recodetx.com/careers/

#CareerOpportunities #BPTW #PatientFirst

Metric
Company Name	ReCode Therapeutics	MOMA Therapeutics	Prenosis
Symbol
MSH ID	COM:RECODETX	COM:MOMATX	COM:PRENOSIS
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage
Employee Count	130
Website	recodetx.com	momatx.com	prenosis.com
LinkedIn	recode-therapeutics		prenosis
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:RECODETX

ReCode Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue